drug

Promising Alzheimer's drug needs to be studied for safety, researchers say

Promising Alzheimer’s drug needs to be studied for safety, researchers say

Comment this story Comment An experimental drug for Alzheimer’s disease moderately slowed the effects of the disease, but was linked to patient safety risks that warrant longer clinical trials, according to a study published Tuesday evening. The study, published in the New England Journal of Medicine, found that a drug developed by Tokyo-based Eisai and …

Promising Alzheimer’s drug needs to be studied for safety, researchers say Read More »

Roche's Alzheimer's drug fails in long-awaited trial

Roche’s Alzheimer’s drug fails in long-awaited trial

Trials show small benefit, but without statistical validity Roche setback leaves Biogen and Eisai as leaders in the field It’s up to Roche’s CEO-designate to revive development fortunes Roche shares down 3.4%, its development partner Morphosys down 29% Nov 14 (Reuters) – Roche’s (ROG.S) Alzheimer’s drug candidate has not been shown to slow the progression …

Roche’s Alzheimer’s drug fails in long-awaited trial Read More »